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The challenges of lung cancer radiotherapy are intra/inter-fraction tumor/organ anatomy/motion changes and the need to
spare surrounding critical structures. Evolving radiotherapy technologies, such as four-dimensional (4D) image-based motion
management, daily on-board imaging and adaptive radiotherapy based on volumetric images over the course of radiotherapy,
have enabled us to deliver higher dose to target while minimizing normal tissue toxicities. The image-guided radiotherapy adapted
to changes of motion and anatomy has made the radiotherapy more precise and allowed ablative dose delivered to the target
using novel treatment approaches such as intensity-modulated radiation therapy, stereotactic body radiation therapy, and proton
therapy in lung cancer, techniques used to be considered very sensitive to motion change. Future clinical trials using real time
tracking and biological adaptive radiotherapy based on functional images are proposed.
1.Introduction
The treatment of lung cancer with radiation has under-
gone signiﬁcant improvements over the past decade. These
improvements can be grouped under three diﬀerent cat-
egories. First, it is possible to better delineate the target
volume through the advancement of imaging such as
positron emission tomography (PET) fusion [1, 2]. Second,
there has been an increase in the utilization of radiation
planning and delivery systems such as intensity-modulated
radiation therapy (IMRT) [3], stereotactic body radiation
therapy (SBRT) [4], and proton therapy [5] that allow more
conformal delivery of radiation to achieve dose escalation
whileminimizingtoxicitytonormalstructures[6,7].Finally,
the advancement of imaging modalities available during the
planning and delivery process has made it feasible to adapt
the target volume, both within a given fraction of treatment
and between fractions, for such factors as internal motion,
tumor response, anatomical changes, and weight loss. With
the availability of 4D CT—(four-dimensional computerized
tomography)—based radiotherapy planning and on-board
imaging (OBI), accurate positioning of the target using daily
image guidance may result in many advantages, such as a
decreased probability of target miss, smaller setup margins,
and less normal tissue exposed to high radiation doses. In
addition, novel treatment adaptation algorithms can provide
more eﬀective modiﬁcation of treatment plans to adapt to
the changes in a patient’s anatomy and organ motion during
and/or between (intra- and/or inter-) treatment fractions.
Thislattercategoryofinnovationshasbeentermed“adaptive
radiotherapy,” and will be the focus of this paper.
In this examination of adaptive radiation in the setting of
lung cancer, we will assess the impact of this development
in SBRT, conventionally fractionated IMRT, and proton
therapy. We will ﬁrst deﬁne key terms in adaptive radiation,
and will then review prior studies assessing the magnitude of
intrafractional changes, which we deﬁne as changes within
a given fraction of radiation, from setup to delivery. This
discussion will be followed by the eﬀect of these changes
on delivered dose and speciﬁc planning techniques that
have been utilized to decrease this variation, speciﬁcally
cone beam computed tomography (CBCT) and respiratory
gating.Wewillthenfocusoninterfractionchangesthatoccur
during the length of treatment (over a period of several
weeks), such as changes in tumor mobility, tumor volume,
anatomy, and body weight, and examine speciﬁc studies
that assess the impact of adaptive planning on improving
dose distributions in these setting. Finally, we will appraise
future directions of adaptive radiation, including selective
dose escalation through the visualization of nonresponsive2 Journal of Oncology
regions and internal tracking to monitor intrafraction
motion in real-time, both of which may be able to allow
for further sparing of critical structures while maintaining
accurate delivery for treatment of this aggressive disease.
2. ImportantDeﬁnitions inAdaptive
Radiation for Lung Cancer
AsadaptedfromtheInternationalCommissiononRadiation
Units (ICRU) Report no. 50: [8].
2.1. GTV (Gross Tumor Volume). Tumor visible by any ima-
ging modality, to include both the primary tumor and any
involved lymph nodes. Lymph nodes greater than 1cm in
size in the shortest axis are generally considered positive for
disease [9], but functional imaging such as PET scanning is
critical for target delineation [10, 11].
2.2. CTV (Clinical Target Volume). The anatomically deﬁned
region at risk for microscopic disease. This region cannot be
visualized as a discrete structure with radiographic imaging,
and the extent has been deﬁned by surgical series with
pathologic correlates, as well as autopsy series. As deﬁned
by Giraud et al., based on NSCLC surgical specimens, an
appropriate GTV to CTV margin for adenocarcinoma is
8mm,andforsquamouscellcarcinoma,6mm[12].Another
study found that in stage I adenocarcinoma, a margin of
9mm is suﬃcient to cover 90% of disease [13]. In terms
of mediastinal disease, a GTV to CTV margin has not been
rigorously analyzed, but based on an abstract presented at
the 2006 meeting of the American Society for Therapeutic
Radiology and Oncology that found a maximal microscopic
extension of lymph nodes is between 0.5 and 8.9mm [14],
we routinely use margins of 8mm for nodal disease.
2.3. ITV (Internal Target Volume). CTV with a margin to
account for organ motion; or, in other words, changes in
the size, shape, and position of the target during treatment
[15]. Delineating the ITV from 4D CT images involves
assessing the target volume (CTV) on expiratory-phase
images and then registering the outline to the images from
other phases to create a union of target contours enclosing
all possible positions of the target. An alternative method
is to create a maximum intensity projection (MIP) image
by combining data from the multiple CT data sets with
data from the whole-breath cycle and modifying the ITV by
visuallyverifyingthetargetvolumethroughoutthebreathing
phases (typically 10). In this process, attention should be
paid to irregular breathing and breathing pattern variations
during each treatment session and over the entire treatment
course, as well as to the eﬀects of these irregularities on the
ITV margin.
Because it is often more straightforward to delineate
the boundaries of the gross tumor volume with motion on
4D CT image data sets as opposed to the clinical target
volume, we previously proposed the concept of the internal
gross tumor volume (iGTV), which envelops the GTV motion
throughout the whole-breath cycle [16]. In this process,
rather than delineating the GTV, expanding to the CTV,
and then adding the ITV, the GTV is contoured, motion is
assessed as outlined above (i.e., through the MIP images or
through all breathing phases), and this target is expanded
to the iGTV. Then, the iGTV is expanded to the ITV (ITV
= iGTV + CTV). This latter method is what is commonly
utilized at our institution to account for organ motion in the
treatment of NSCLC.
2.4. PTV (Planning Target Volume). CTV plus a margin to
account for both organ motion and daily setup. Or, the ITV
withamargintoaccountfordailysetup.Theapplicationand
revision of margins for the PTV and ITV will be discussed in
detail below.
3. The Role of AdaptiveRadiotherapy in
IntrafractionAdaptivePlanning
3.1. Quantitating Intrafractional Tumor Motion. Several
studies have attempted to quantitate intrafraction tumor
motion with radiation therapy. Bissonnette et al. examined
CBCT images during each fraction of 18 patients receiving
SBRT for medically inoperable Stage I nonsmall cell lung
cancer (NSCLC). The CBCT images were performed at
the beginning, midpoint, and end of each fraction to
determine diﬀerences in tumor motion amplitude. The
authors found that at a mean time of 35 minutes (from
the beginning of each treatment to the end), the mean
change in tumor amplitude was 0.4, 1.0, and 0.4mm in
the medial-lateral (ML), superior-inferior (SI), and anterior-
posterior (AP) directions, respectively. These values were
not statistically signiﬁcantly diﬀerent when compared to
the initial respiratory correlated (4D) CT scan, other than
in patients in which abdominal compression was used, in
which longer times on the couch were hypothesized to
increase these diﬀerences [17]. In another study, Michalski
et al. compared the amount of motion between the three
aforementioned directional axes (ML, SI, and AP) in 23
patients undergoing 4D CT scans. The authors found that
the largest intrafractional extent of motion was in the SI
direction,withthelargestrangebeing3.59cm[18].Asimilar
study from our institution also assessed respiration-induced
tumor motion during radiation for lung cancer. This study
by Liu et al. assessed 166 tumors in 152 lung cancer patients,
57% of whom had stage III or IV disease. The authors also
found that the largest axis of motion was in the SI direction,
and that 39% of tumors moved >0.5cm in this direction,
compared to 1.8% and 5.4% in the ML and AP directions,
respectively. Tumor motion was also found to be correlated
with the amount of diaphragm motion, the SI location of
the tumor, and the size of the GTV, with smaller tumors
exhibiting a greater degree of intrafractional motion [19].
A study by Thomas et al. demonstrated that mediastinal
nodal regions also move substantially with the respiratory
cycle, generally posteriorly and superiorly with exhalation,
and that inferior nodal stations exhibit a greater degree of
motion, such that the same issues with respiratory variation
in parenchymal tumors can also be applied to mediastinal
disease [20].Journal of Oncology 3
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Figure 1: Volumetric on-board Kilovoltage cone-beam CT imag-
ing.
Thus, it can be concluded that: (1) inferior tumors move
more than superior tumors, (2) the largest axis of motion is
in the SI direction, and (3) mediastinal lymph nodes are also
subject to a signiﬁcant degree of tumor motion.
3.2. On-Board Imaging in Treatment for NSCLC. There are
several methods to detect setup error and intrafractional
variation during radiation therapy for NSCLC.
3.2.1. Electronic 2D Imaging with Radiographs. In this tech-
nique, two-dimensional images are composed in the treat-
mentposition,andthepatientissetuponpatientanatomical
landmarks such as bony anatomy. Historically, megavoltage
(MV) imaging had been used, but the images produced
with this technique were generally of poor image quality
and exposed the patient to high radiation doses. In the
past decade, the utilization of kilovoltage (kV) imaging has
increased, which has improved image quality and decreased
radiation exposure.
3.2.2.KilovoltageorMegavoltageCone-BeamCTScanning. In
this method, a CT image is reconstructed on the treatment
table from a set of projection images acquired at multiple
angles around the patient. Image reconstruction with this
modality diﬀers from conventional CT scans in that rather
than a linear array of detectors being back projected to con-
struct a 2D slice, a “detector array” (e.g., a ﬂat-panel portal
i m a g e r )i su s e dt or e c o n s t r u c ta3 Dd a t as e t[ 21]. (Figure 1)
It follows that the CT images that are a result of this process
are theoretically superior in improving intrafractional error
as compared to portal images, and multiple studies have
exhibited this improvement, particularly in SBRT where
longer treatment times can lead to greater instability and less
reproducibility of the setup process.
3.3.SetupErrorsasaCauseofIntrafractionalVariationandthe
Role of On-Board Imaging. Intrafraction treatment variation
has two components in lung cancer: uncertainties in patient
positioning and variations in internal motion. Nelson et
al. examined the eﬀect of lung tumor motion and setup
uncertainties using implanted ﬁducial markers. The authors
found that systematic and random uncertainties ranged
between 4 and 6mm in all three directions [22]. With daily
portal imaging, the authors found in a subsequent study that
alignment based on implanted ﬁducials reduced systematic
errors in the left-right and superior-inferior direction each
by 3mm [23]. As a result, daily portal imaging is often
utilizedtodecreasesetuperrorinconventionallyfractionated
regimens, with a daily setup error of up to 5mm.
Borst et al. compared CBCT setup with portal imaging
in daily setup for 62 patients in 524 scans with NSCLC,
and found that CBCT reduced the setup error to less
than 5mm, from 51% of patients with setup errors more
than 5mm to 2% with CBCT [24]. Bissonnette et al.
assessed the accuracy of CBCT in RT for lung cancer in
patients receiving both SBRT for early-stage malignancies
andinthosepatientsundergoingconventionallyfractionated
treatment for locally advanced disease. The couch position
was adjusted for discrepancies greater than 3mm between
the initial setup and treatment images. The accuracy of
this adjustment was then veriﬁed with a second CBCT.
Without CBCT adjustments, positioning errors were found
to exceed 5mm in approximately 55% of patients. However,
CBCT decreased this error, such that systematic and random
setup margin was within 3mm for 82% of fractions in the
SBRT group, and between 76% and 84% of the patients in
the conventionally fractionated group [25]. Similar ﬁndings
were published by Grills et al., who found that CBCT
image guidance signiﬁcantly decreased setup margins in
SBRT, with calculated precorrection population margins of
9–13mm and 10–14mm with a stereotactic body frame and
alpha cradle, respectively, while these same margins were
1-2mm and 2-3mm postcorrection, and 2–4mm and 2–
5mm postreatment, respectively [26]. The conclusion of
these studies is that consistent CBCT imaging can decrease
the amount of systematic and random error on a daily basis
(to within 3mm), and thus decrease intrafraction variation.
3.4. Methods of Breathing Control. Lung tumors diﬀer from
many other treatment sites in that internal motion can
account for large variations in tumor position, and as a
result, dosimetry. Several studies have exhibited this ﬁnding.
Mechalakos et al. examined treatment plans for 12 patients
receiving radiation therapy for NSCLC. The authors found
that the dose to 95% of the gross tumor volume (GTV), also
known as the D95, changed on an average of only 1.4% when
normal breathing eﬀects were incorporated. However, with
“heavy breathers,” the D95 changed almost 10%. Therefore,
the authors concluded that while the chance of a 10% or
greater decrease in D95 was less than 4%, patients with a
large degree of respiratory motion could have signiﬁcant
eﬀects, and thus these patients should be identiﬁed [27]. A
study from the University Hospital Rotterdam in the Nether-
lands found that with a GTV to planning target volume
(PTV) margin of 1.5cm, approximately 11% of the tumor
was not covered in mobile tumors. Engelsman et al. found
that when combined with setup error, respiratory motion
reduced the tumor control probability (TCP) by almost 9%4 Journal of Oncology
Figure 2: Motion of a tumor in the inferior portion of the lung.
(from 50% to 42%) in patients receiving conventionally
fractionated radiation to 70 Gy in lung tumors [28].
There are several methods in which tumor motion can
be taken into account with the delivery of radiation therapy
and which are utilized at our institution. First, breathing
can be monitored during simulation and the iGTV/ITV can
then be added as a margin to ensure that the tumor is
treated adequately throughout all phases of the respiratory
cycles as outlined above (e.g., if the tumor is noted to move
1.5cm during treatment, then a 1.5cm margin, termed the
ITV/iGTV, is added to account for this respiratory motion.).
Thisstrategyisoftendenotedthe “free-breathingtechnique.”
If 4D CT imaging is not available at the institution, then
an alternative method to account for respiratory motion is
through the use of breath-hold spiral CT simulation. In this
method, the patient is instructed to hold his breath during
simulation, both at end inspiration and expiration. Images
are then taken at end-inspiration and end-expiration, such
that an ITV can be generated by combining the two CTVs
from the inspiratory and expiratory scans.
A disadvantage to the free-breathing method is that in
tumors that have a large magnitude of motion, the amount
of normal tissue that is treated can be relatively large,
since radiation is being delivered throughout the breathing
cycle. Therefore, an alternative method of radiation delivery
is to instruct the patient to hold their breath during
treatment and activate the radiation while the tumor is in
this full inspiratory, ﬁxed position. The disadvantage to this
technique (often termed deep inspiratory breath hold, or
DISB) is that it requires full cooperation of the patient, in
that the patient will need to hold their breath for 15 seconds
or longer. As an alternative to this method, radiation could
be delivered in either a relaxed inspiratory position or in
expiration, which is often more reproducible than DISB.
In patients that are not able to comply with any of
these instructions, a third method of delivering radiation
in tumors that have a great deal of motion is through a
ventilatory-gated approach, during which the radiation
beam is coordinated with the respiratory cycle through the
placement of externally placed ﬁducial markers. Or, in other
words, the radiation is only delivered at certain phases, most
typicallyfullexpiration[29].Thistypeoftherapyisgenerally
most useful for tumors less than 5cm in diameter and for a
tumor motion of greater than 1cm. Figure 2 demonstrates
the motion of a tumor in the inferior portion of the lung.
It is evident that with timed radiation delivery, a great deal
of normal tissue could be spared by reducing the treatment
margins.
3.5. Dosimetric Advantages of Breathing Control in NSCLC.
Many studies have shown that accounting for breathing
motion can improve dosimetric parameters. Vlachaki et al.
assessed 10 patients with lung tumors to determine the
eﬀect of respiratory gating on dosimetry. Gated images were
acquired at full inspiration, full expiration, and at each
quartile of respiratory movement. The authors found that
gating led to higher minimum target volume doses, and that
the V20 was reduced from 35% to 26% for gated plans.
The mean lung, heart, and esophageal doses were also lower
with gated plans. The authors concluded that gating could
improve the dose to normal structures while maintaining
targettissuecoverage[30].Furtherstudieshavecorroborated
these ﬁndings. Underberg et al. examined 31 patients simu-
lated with 4D CT scans and compared the dose to normal
tissue in three diﬀerent techniques to account for breathing
motion in target delineation: (1) standard, population-based
margins to account for internal motion, (2) the generation
of an ITV based on tumor mobility in three consecutive
phases, and (3) a PTV generated from respiratory gating.
The authors concluded that utilizing “standard population-
based” margins led to unnecessary normal tissue irradiation,
and that the risk was best minimized if gating was utilized
[31]. A recent study from Fox Chase Cancer Center arrived
at a similar conclusion, in that 4D CT-based treatment
planning maintains target coverage while reducing normal
tissue dose [32].
It is important to note that the intrafractional adaptive
radiotherapy techniques of CBCT and breathing control are
not mutually exclusive, but in contrast should be utilized
together to optimize the therapeutic ratio, as demonstratedJournal of Oncology 5
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Figure 3: Impact of tumor shrinkage in proton isodose distribution over 7 weeks of treatment.
by several studies. Koch et al. found that the relationship
between internal lung motion and skin ﬁducial motion is
complex and unpredictable, and that the AP motion of
tumors correlated poorly with skin surface markers. They
also found that there is signiﬁcant intersubject variability
[33].Inafollow-upstudy,Liuetal.foundthatthisvariability
(and in turn, the target volume margins) could be substan-
tially reduced with the use of respiratory gating techniques
[34]. And in a study by Nelson et al., the authors assessed
the margins necessary to account for uncertainties in tumor
position withrespiratory gating, image-guidedpatient setup,
neither, or both. The authors found that utilizing both
methodssimultaneouslyallowedforthegreatestreductionin
margins that completely encompassed the tumor, and there-
fore concluded that when respiratory motion management is
used, it should be used “in conjunction with image-guided
patient setup in order to reduce the overall treatment margin
eﬀectively” [35].
3.6. Real-Time Tracking in NSCLC. Another delivery system
of increasingly widespread use is Cyberknife therapy, which
utilizes a stereotactic guidance system designed primarily
for radiosurgery in multiple organ systems. The premise
behind this system is that the linear accelerator is mounted
on a robotic arm, which can then track the target during
treatment. Cyberknife has been reported in single institution
studies in the setting of SBRT for lung cancers. For example,
Le et al. reported 32 patients with lung tumors treated in a
dose escalation study using single fractions, and found a 1-
year local control rate of 91% for doses greater than 20Gy
and at doses less than 25Gy there was no signiﬁcant toxicity
[36]. Brown et al. assessed the eﬃcacy of this technique in
peripherally located stage I nonsmall cell lung cancers. In a
cohort of 31 patients, the authors reported no grade 3 or
higher toxicities and 1-year local control rates of 93.2% [37].
Further studies on this technique will continue to deﬁne its
role in adaptive radiotherapy and the deﬁnitive treatment of
NSCLC.
More recently, Novalis Tx provides stereo X-ray targeting
and adaptive gating using ExacTrac X-ray 6D and snap
veriﬁcation system. Videtic et al. reported 94.4% local
control with minimal toxicities with 50Gy delivered in 5
fractions using the Novalis/Brain LAB system. All of these
novel systems may provide an optimal treatment for clinical
challenging cases such as patients with poor lung function
and/or lesions close to critical structures [38].
4. The Role of AdaptiveRadiotherapy in
InterfractionalChanges
Several factors change during the course of radiation can
aﬀect target and normal tissue dose. These factors include6 Journal of Oncology
but are not limited to changes in tumor size, alterations
in tissue anatomy, variations in respiratory patterns, and
reductions in patient weight. In this setting, adaptive radio-
therapy refers to repeat assessment of the target volume,
either through repeat CBCT, 4D imaging, or both.
4.1. Changes in Tissue Anatomy, Respiratory Patterns, and
Weight with IMRT and 3D-Conformal Therapy. Multiple
studies have been performed examining causative factors of
interfractional changes and the eﬀect of these variations on
dosimetry throughout treatment. Redmond at al. examined
10 patients to determine whether tumor excursion due
to respiratory motion was stable when comparing images
acquired at the time of simulation with those during
treatment. The authors found that while there was interfrac-
tion consistency in tumor excursion during treatment, the
relationship between the GTV and other anatomic structures
between respiratory changes varied with rescanning. The
authors therefore expressed caution in relying on “surrogate
anatomicmarkers”toassesstumormotionthroughouttreat-
ment [39]. Bosmans et al. assessed 23 patients with locally
advanced NSCLC who underwent CT-PET and respiration-
correlated imaging prior to treatment, and repeated at the
ﬁrst and second weeks after the start of radiation. The
authors observed that while changes in tumor motion were
relatively small, there was a great deal of variation in tumor
size during therapy. These changes ranged from an increase
ingreaterthan30%toadecreaseofthesamemagnitude.The
authors concluded that the changes in tumor size warranted
assessment for replanning during the course of therapy [40].
Van Zwienen et al. found that clinically evident regression
occurred in approximately 40% of patients undergoing
deﬁnitive treatment for NSCLC, with approximately 10% of
patients undergoing >25% reduction in size by week three
and in 24 out of 114 patients by week four. Larger reductions
were also associated with reduction atelectasis [41]. A study
from Johns Hopkins University supported this ﬁnding of
large variations in the GTV, and thus also recommended
an adaptive approach in conventionally fractionated patients
[42].
Britton et al. analyzed the eﬀect of gross tumor volume
regression and motion changes during the course of radia-
tion therapy in locally advanced NSCLC at MD Anderson
Cancer Center. The authors found that in 8 patients with
weekly 4DCT data sets, the tumor volume was reduced by a
rangeof15–71%.Therewasalsonotedtobeincreasedtumor
mobility in the SI and AP directions throughout treatment,
without any clear trends in tumor motion [43]. In a follow-
up study at the same institution, the authors found that the
dose to 95% of the PTV and ITV with weekly CT scans
changedbyapproximately12%and2.5%,respectively.While
thelungV20andmeanlungdoseonlyincreasedbyameanof
3.1% and 2.2%, respectively, the spinal cord dose changed by
an average of 34.3% [44]. These studies together imply that
continued assessment of the target volume is recommended
and is essential in tumors that lie near the spinal cord.
Figure 3 demonstrates the signiﬁcant reduction in size of a
tumor throughout treatment, and the large eﬀect that this
reduction has on the dose distribution.
A study from Denmark demonstrated that anatomical
and motion changes persist even with respiratory gating.
In a study by Juher-Nottrup et al., ten patients receiving
60Gy in 2Gy fractions underwent serial 4D CT scans during
treatment.Theauthorsfoundthattheinterfractionaloverlap
of lung tumors was only 80%–87% when bony landmarks
were used with a gating technique, and that this overlap
decreased to 70%–76% when skin tattoos were present.
With mediastinal tumors, the overlap was 60%–65% and
41%–47%, respectively. It can therefore be concluded that
gating does not preclude interfractional adaptive planning in
patients with lung or mediastinal tumors [45].
Weight loss can be a factor in changing anatomy and in
turnthedosetotargetvolume,suchasinthecaseofapatient
that loses a great deal of weight that causes the eﬀective beam
path to change. Some investigators have questioned whether
weight loss in itself can be a cause of setup error during the
course of treatment due to factors such as changes in the
position of skin marks. Johansen et al. attempted to answer
this question by evaluating the relationship of interfractional
setup errors with body mass index and weight loss. The
authors assessed 34 head and neck cancer patients and 20
lung cancer patients who received serial CBCT images to
evaluate whether there was a change in 3D position between
the initial CBCT scans and those from the 10th and 20th
treatment session. The study did not ﬁnd a statistically
signiﬁcant correlation between setup error and either patient
bodymassindexorweightloss[46].Therefore,whileitisstill
recommended that replanning is performed on the basis of
weight changes during treatment, interfractional changes as
a result of weight loss may be more a function of subsequent
anatomical variations rather than true setup error.
4.2. Interfractional Adaptive Planning in SBRT. Similar stud-
ies as above quantitating interfractional dosimetric error
have been performed in patients being treated with SBRT.
Matsugi et al. examined 4D CT scans for 8 patients being
treated with SBRT, to measure interfraction variations in
position and the size of target volumes with this technique.
In contrast to a conventionally fractionated treatment which
is several weeks in duration, the authors found that the size
of the GTV did not change signiﬁcantly during treatment
and that variations in motion range and position were also
small[47].SimilarconclusionsweremadebyHaasbeeketal.,
who found that the dosimetric consequences of interfraction
adaptive planning were small [48]. However, the target
volume is usually small in SBRT and a large fraction size
is delivered in less than 5 fractions; therefore, missing a
small volume of target even just in one fraction can cause
signiﬁcant underdosing of the tumor and/or overdosing
surrounding normal tissues. We therefore reiterate that we
recommend daily volumetric veriﬁcation for target coverage
in SBRT.
4.3. Interfractional Adaptive Planning in Proton Therapy.
Withtheadventofprotontherapy,investigatorshaverecently
begun to examine the eﬀect of interfractional motion and
anatomic changes on dose distribution with this technique.
This issue is particularly important with protons because theJournal of Oncology 7
impact of motion and anatomy changes is more signiﬁcant
in proton compared with photon (Figure 3). Hui and Chang
et al. acquired weekly 4D-CT scans on 8 patients with
locally advanced NSCLC treated with IMRT. A conformal
passive scattering plan was generated for each patient and
compared with IMRT plan over 7 weeks of radiotherapy.
The authors found that normal tissue doses were increased
and CTV coverage was signiﬁcantly compromised in one
patient (with a decrease in approximately 8%) with proton
therapy but much less signiﬁcantly in the IMRT plan. The
authors concluded that proton therapy is more sensitive to
motion and anatomy changes compared with photon and
interfractional adaptive planning and is indicated in select
patients [49].
4.4. Guidelines for Adaptive Planning in Nonsmall Cell
Lung Cancer. At our institution, all patients undergo a 4D
CT simulation to assess for internal motion. Patients are
immobilized with an upper body cradleand T-bar, which has
a daily setup uncertainty of approximately 7mm. At the time
of simulation, patients are evaluated for breathing patterns
and tumor motion. In patients whose tumor motion is less
than 1cm, a “free-breathing” technique is typically used,
with the creation of an ITV or iGTV and radiation treatment
delivery in all phases of the breathing cycle. If the target
volume moves more than 1cm and the patient can breathe
reproducibly, then radiation is either timed with certain
phases of the breathing cycle while the patient breathes freely
(ventilatory gated technique), or the patient is instructed to
hold their breath for at least 15 seconds while radiation is
deliveredatdeepinspiration (DISB).Weutilizevisualand/or
audio feedback guidance for patients who can comply with
these devices.
Patients undergoing standard fractionated regimens are
initially set up daily with kV imaging for veriﬁcation,
which reduces the setup margin to 5mm. All patients are
assessed for concordance between bony/skin landmarks and
tumor setup. If it is found that these setup parameters are
discordant, or that the tumor is changing rapidly, CBCT is
employed, which reduces the ITV to PTV margin to 3mm.
All patients receiving SBRT undergo volumetric veriﬁcation
of set up and motion such as CBCT prior to each treatment.
Repeat 4D simulations are performed selectively at the
physician’s discretion in patients with NSCLC undergoing
conventional fractionation for 6-7 weeks and are routinely
performed in patients with small cell lung carcinoma
undergoing hyperfractionated (twice a day) or dose esca-
lated/accelerated radiotherapy for 3 to 7 weeks. Adaptive 4D
replanning is performed if motion/anatomy changes may
change the target coverage and/or increase dose to surround-
ing critical structures. Interfractional adaptive 4D planning
is not routinely utilized on patients undergoing SBRT (4-10
fractions), as these patients receive daily volumetric imaging.
I ti sn o t a b l et h a ti ti ss t i l lu n c l e a ri ft a r g e tv o l u m e
reductions are warranted in the scenario of GTV shrinkage
during the course of radiotherapy [50–52]. Some physicians
advocate an approach in which the target volume remains
constant due to concerns for residual microscopic disease. To
address these concerns, one option is to deliver at least 50Gy,
the standard dose for microscopic disease, to the original
target volume, and then to boost the reduced volume to
the full dose. Well-designed studies addressing this issue are
needed.
5. FutureDirectionsin AdaptiveRadiotherapy
New technologies are evolving to improve adaptive radiation
therapy, such that the high dose region is focused on the tar-
get while sparing critical normal tissues. Treatment planning
basedon4DCTimagesandon-boardimage-guidedadaptive
treatmentdeliveryassiststheradiationoncologistintracking
tumor motion and targeting the tumor precisely.
As advancements in technology have allowed for both
intra- and interfraction replanning, investigators have begun
to assess whether or not the response of tumor during
treatment can lead to changes in total dose to portions of
thetargetvolumebasedonthemagnitudeoftumorresponse
to the initial phase of treatment (image-guided adaptive
treatment). This strategy is particularly relevant because
severalstudieshaveshownthatdoseescalationinlungcancer
improves local control [53]. Furthermore, prior studies have
demonstratedthatregionswithhighSUVsandhypoxicareas
are more likely to exhibit local failure when treated with
radiation [54, 55]. The information thus suggests that the
radioresistance and propensity for distant metastasis in gross
disease varies based on factors other than histologic type,
stage, and tumor grade. It is in this realm that adaptive dose
escalation may have a role in addition to the utility of IMRT
dose painting.
Feng et al. performed a pilot study in which 14 patients
with NSCLC underwent repeat PET-CT scans prior to the
start of radiation therapy and mid-way through treatment.
Boost ﬁelds were then designed based on residual PET
avidity. In this dosimetric study, the authors found that this
method allowed for a mean dose escalation of 58Gy or a
reduction in normal tissue complication probability (NTCP)
ofupto3%inpatientswithareductionintumorsize[56].In
a similar study, Gillham et al. performed an additional PET-
CT scan in week 5 or 6 of radiotherapy for patients being
treated with localized inoperable NSCLC to 66Gy in 2Gy
fractions. The authors found that there was a median PTV
reduction of 20%, and that in this dosimetric study, dose
escalation to 78 Gy was feasible in four out of ten patients
without exceeding normal tissue constraints [57]. Future
studies will determine whether this technique of adaptive
dose escalation is feasible from a clinical standpoint without
increasing toxicity and while maintaining tumor control.
An additional technologic advancement in the context
of adaptive radiotherapy is the development of “real-time”
tracking of tumor motion so that the treatment can be
actively and variably adapted in concordance with intrafrac-
tional changes. In addition to Cyberknife, which has been
used clinically as discussed above, another commercially
available system is the Calypso Medical three- or four-
dimensional electromagnetic tracking system. The system
has undergone initial assessment in a wide variety of tumor
sites and several studies have been published describing the
technique. For example, Smith et al. compared dosimetric8 Journal of Oncology
results with and without real-time tracking. The authors
found that the dose proﬁles were comparable with an ide-
alized gating algorithm while minimizing the uncertainties
inherent in the use of anatomical surrogates for target
location, with a high level of eﬃciency [58]. In a follow-
up study, the same authors proposed a method for linear
accelerator gating with wireless internal ﬁducial markers
without the requirement for ionizing radiation for imaging,
leading to improvements in the dose distribution [58].
Adaptive radiotherapy may improve tumor control in
lung cancer by reducing target misses, escalating target dose,
and minimizing side eﬀects by avoiding critical structures
over the course of radiotherapy. More prospective studies are
needed to implement these technologies and validate their
eﬃcacies.
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